F F Rahbari-Oskoui1, J L Abramson2, A M Bruckman3, A B Chapman4, G A Cotsonis5, S A Johnson6, D L Bliwise7. 1. Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: frahbar@emory.edu. 2. Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: jeromeabramson@gmail.com. 3. Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: adam.bruckman@emory.edu. 4. Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: achapman1@bsd.uchicago.edu. 5. School of Public Health, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: gcotson@emory.edu. 6. Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: sarah.ann.johnson@emory.edu. 7. Department of Neurology, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: dbliwis@emory.edu.
Abstract
OBJECTIVES: This preliminary study tested whether a high-dose, sustained-release form of melatonin reduced 24-hour blood pressure in African-Americans. DESIGN: Randomized, placebo-controlled, crossover pilot study of 40 self-defined African-American patients with essential hypertension. SETTINGS/LOCATION: Urban, academic medical center and associated outpatient clinics. INTERVENTIONS: Patients ingested either melatonin (high dose [24 mg], sustained-release formulation] or placebo in randomized order over a 4-week period. OUTCOME MEASURES: Mean nighttime and daytime systolic and diastolic blood pressures, as measured with 24-hour ambulatory blood pressure monitors. The primary outcome was mean nighttime systolic blood pressure. RESULTS: There were no statistically differences between melatonin and placebo conditions in mean nighttime or daytime systolic or diastolic blood pressures. CONCLUSIONS: In contrast with studies in other populations, this preliminary study showed that nighttime dosing of continuous-release melatonin had no significant effect on nocturnal blood pressure in African Americans with essential hypertension when compared to placebo.
RCT Entities:
OBJECTIVES: This preliminary study tested whether a high-dose, sustained-release form of melatonin reduced 24-hour blood pressure in African-Americans. DESIGN: Randomized, placebo-controlled, crossover pilot study of 40 self-defined African-American patients with essential hypertension. SETTINGS/LOCATION: Urban, academic medical center and associated outpatient clinics. INTERVENTIONS:Patients ingested either melatonin (high dose [24 mg], sustained-release formulation] or placebo in randomized order over a 4-week period. OUTCOME MEASURES: Mean nighttime and daytime systolic and diastolic blood pressures, as measured with 24-hour ambulatory blood pressure monitors. The primary outcome was mean nighttime systolic blood pressure. RESULTS: There were no statistically differences between melatonin and placebo conditions in mean nighttime or daytime systolic or diastolic blood pressures. CONCLUSIONS: In contrast with studies in other populations, this preliminary study showed that nighttime dosing of continuous-release melatonin had no significant effect on nocturnal blood pressure in African Americans with essential hypertension when compared to placebo.
Authors: Mohammad Tobeiha; Ameneh Jafari; Sara Fadaei; Seyed Mohammad Ali Mirazimi; Fatemeh Dashti; Atefeh Amiri; Haroon Khan; Zatollah Asemi; Russel J Reiter; Michael R Hamblin; Hamed Mirzaei Journal: Front Cardiovasc Med Date: 2022-06-20